

HIV

Summary and recommendations

Walter Jaoko, Shabbar Jaffar

- Prevention is a high priority

Microbicides and vaccines

- Good safety data available and hints of efficacy.
- This research must continue. Other microbicide agents need evaluation (e.g. antiretroviral-based microbicides) as well as vaccines.
- Big money needed for trials

PrEP

- Trials underway – reporting 2010-11
- No obvious research gap

Clinical questions

- When to start HIV treatment?
 - remains a research gap
- When do we switch treatment and what to switch to?
- How can reduce the high mortality just prior to and just after antiretroviral initiation?
 - EDCTP call on this
- Could we scale-up VCT and begin HIV treatment immediately for all?
 - Mixed feelings about this strategy;
 - but prevention packages tailored to specific populations is vital.
 - For example prevention among positives, particularly among couples

Delivery systems

- Research will be needed to determine how to scale-up once proof of concept is demonstrated
 - microbicides
 - PrEP
 - HIV treatment
- Important that funding agencies put high on agenda research on delivery models